Dizlin Pharmaceuticals AB is a Swedish research-based pharmaceutical development company focusing on innovative treatments for late stages of Parkinson's disease. The company collaborates with the University of Gothenburg and Linköping University to conduct research in this field. Dizlin Pharmaceuticals has developed a patented method for treating advanced stages of Parkinson's and currently has two products in the late phase development stage: Infudopa IntraV™, administered intravenously to minimize surgical risks for Parkinson's patients, and Infudopa SubC™, administered as a continuous subcutaneous infusion. Founded in 2008, the company is committed to addressing diseases of the central nervous system. Notably, there is no information available regarding their industries, headquarters, last investment, or last investment investors.
There is no investment information
No recent news or press coverage available for Dizlin Pharmaceuticals AB.